sofosbuvir CAS NO.1190307-88-0

Hengxun pharmaceutical is a leading manufacturer and supplier of chemicals in China. We develop, produce and distribute high quality pharmaceuticals, intermediates, special chemicals and other fine chemicals. 

We could give you: 
1.Best quality in your requirement 
2.Competitive price in China market 
3.mature Technical support 
4.Professional logistic support 
All we want is win-win business. Send yr. inquiries, you will get it!

Sofosbuvir (brand names Sovaldi and Virunon) is a drug used for hepatitis C virus (HCV) infection, with a high cure rate. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It was discovered at Pharmasset and developed by Gilead Sciences.

Sofosbuvir is a component of the first all-oral, interferon-free regimen approved for treating chronic hepatitis C.

In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4. Sofosbuvir treatment regimens last 12 weeks for genotypes 1, 2 and 4, and 24 weeks for treatment of genotype 3. This is typically half the time as with prior treatments. The label further states that sofosbuvir in combination with ribavirin may be considered for patients infected with genotype 1 who are interferon-ineligible.Sofosbuvir costs have been quoted by the media as $84,000 for 12 weeks of treatment and $168,000 for the 24 weeks, and variously as £35,000 for 12 weeks in the UK which some patient advocates have criticized as unaffordable, but which may well change rapidly downwards if the drug is formally approved